nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2C—Sorafenib—liver cancer	0.229	0.542	CbGbCtD
Duloxetine—CYP1A2—Sorafenib—liver cancer	0.0832	0.197	CbGbCtD
Duloxetine—CYP2D6—Sorafenib—liver cancer	0.0685	0.162	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—liver cancer	0.0416	0.0986	CbGbCtD
Duloxetine—Dehydration—Epirubicin—liver cancer	0.000727	0.00168	CcSEcCtD
Duloxetine—Hyponatraemia—Doxorubicin—liver cancer	0.000727	0.00168	CcSEcCtD
Duloxetine—Pain in extremity—Doxorubicin—liver cancer	0.000724	0.00167	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000724	0.00167	CcSEcCtD
Duloxetine—Diplopia—Doxorubicin—liver cancer	0.000724	0.00167	CcSEcCtD
Duloxetine—Osteoarthritis—Doxorubicin—liver cancer	0.000724	0.00167	CcSEcCtD
Duloxetine—Liver function test abnormal—Epirubicin—liver cancer	0.000722	0.00167	CcSEcCtD
Duloxetine—Orthostatic hypotension—Epirubicin—liver cancer	0.000714	0.00165	CcSEcCtD
Duloxetine—Abdominal pain upper—Epirubicin—liver cancer	0.000714	0.00165	CcSEcCtD
Duloxetine—Affect lability—Doxorubicin—liver cancer	0.000712	0.00165	CcSEcCtD
Duloxetine—Migraine—Doxorubicin—liver cancer	0.000712	0.00165	CcSEcCtD
Duloxetine—Diarrhoea—Sorafenib—liver cancer	0.000712	0.00165	CcSEcCtD
Duloxetine—Breast disorder—Epirubicin—liver cancer	0.000707	0.00163	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000704	0.00163	CcSEcCtD
Duloxetine—Nasopharyngitis—Epirubicin—liver cancer	0.000699	0.00162	CcSEcCtD
Duloxetine—Face oedema—Doxorubicin—liver cancer	0.000699	0.00162	CcSEcCtD
Duloxetine—Gastritis—Epirubicin—liver cancer	0.000692	0.0016	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00069	0.00159	CcSEcCtD
Duloxetine—Muscular weakness—Epirubicin—liver cancer	0.00069	0.00159	CcSEcCtD
Duloxetine—Dizziness—Sorafenib—liver cancer	0.000688	0.00159	CcSEcCtD
Duloxetine—Mood swings—Doxorubicin—liver cancer	0.000686	0.00159	CcSEcCtD
Duloxetine—Ataxia—Doxorubicin—liver cancer	0.00068	0.00157	CcSEcCtD
Duloxetine—Blood creatinine increased—Doxorubicin—liver cancer	0.000678	0.00157	CcSEcCtD
Duloxetine—Influenza—Epirubicin—liver cancer	0.000676	0.00156	CcSEcCtD
Duloxetine—Dysphagia—Epirubicin—liver cancer	0.000676	0.00156	CcSEcCtD
Duloxetine—Dehydration—Doxorubicin—liver cancer	0.000673	0.00156	CcSEcCtD
Duloxetine—Liver function test abnormal—Doxorubicin—liver cancer	0.000668	0.00154	CcSEcCtD
Duloxetine—Pancreatitis—Epirubicin—liver cancer	0.000663	0.00153	CcSEcCtD
Duloxetine—Vomiting—Sorafenib—liver cancer	0.000661	0.00153	CcSEcCtD
Duloxetine—Orthostatic hypotension—Doxorubicin—liver cancer	0.000661	0.00153	CcSEcCtD
Duloxetine—Abdominal pain upper—Doxorubicin—liver cancer	0.000661	0.00153	CcSEcCtD
Duloxetine—Rash—Sorafenib—liver cancer	0.000656	0.00152	CcSEcCtD
Duloxetine—Dermatitis—Sorafenib—liver cancer	0.000655	0.00151	CcSEcCtD
Duloxetine—Breast disorder—Doxorubicin—liver cancer	0.000654	0.00151	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000652	0.00151	CcSEcCtD
Duloxetine—Headache—Sorafenib—liver cancer	0.000652	0.00151	CcSEcCtD
Duloxetine—Nasopharyngitis—Doxorubicin—liver cancer	0.000647	0.0015	CcSEcCtD
Duloxetine—Gastritis—Doxorubicin—liver cancer	0.00064	0.00148	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000638	0.00148	CcSEcCtD
Duloxetine—Muscular weakness—Doxorubicin—liver cancer	0.000638	0.00148	CcSEcCtD
Duloxetine—Dysuria—Epirubicin—liver cancer	0.000632	0.00146	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Epirubicin—liver cancer	0.000628	0.00145	CcSEcCtD
Duloxetine—Influenza—Doxorubicin—liver cancer	0.000625	0.00145	CcSEcCtD
Duloxetine—Dysphagia—Doxorubicin—liver cancer	0.000625	0.00145	CcSEcCtD
Duloxetine—Pollakiuria—Epirubicin—liver cancer	0.000624	0.00144	CcSEcCtD
Duloxetine—Nausea—Sorafenib—liver cancer	0.000618	0.00143	CcSEcCtD
Duloxetine—Photosensitivity reaction—Epirubicin—liver cancer	0.000617	0.00143	CcSEcCtD
Duloxetine—Weight increased—Epirubicin—liver cancer	0.000615	0.00142	CcSEcCtD
Duloxetine—Pancreatitis—Doxorubicin—liver cancer	0.000613	0.00142	CcSEcCtD
Duloxetine—Weight decreased—Epirubicin—liver cancer	0.000612	0.00141	CcSEcCtD
Duloxetine—Hyperglycaemia—Epirubicin—liver cancer	0.00061	0.00141	CcSEcCtD
Duloxetine—Infestation NOS—Epirubicin—liver cancer	0.000603	0.00139	CcSEcCtD
Duloxetine—Infestation—Epirubicin—liver cancer	0.000603	0.00139	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000598	0.00138	CcSEcCtD
Duloxetine—Renal failure—Epirubicin—liver cancer	0.000592	0.00137	CcSEcCtD
Duloxetine—Stomatitis—Epirubicin—liver cancer	0.000588	0.00136	CcSEcCtD
Duloxetine—Jaundice—Epirubicin—liver cancer	0.000588	0.00136	CcSEcCtD
Duloxetine—Conjunctivitis—Epirubicin—liver cancer	0.000586	0.00135	CcSEcCtD
Duloxetine—Urinary tract infection—Epirubicin—liver cancer	0.000586	0.00135	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—liver cancer	0.000585	0.00135	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000581	0.00134	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—liver cancer	0.000578	0.00134	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—liver cancer	0.000571	0.00132	CcSEcCtD
Duloxetine—Hepatobiliary disease—Epirubicin—liver cancer	0.00057	0.00132	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—liver cancer	0.000569	0.00132	CcSEcCtD
Duloxetine—Epistaxis—Epirubicin—liver cancer	0.000568	0.00131	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—liver cancer	0.000566	0.00131	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—liver cancer	0.000564	0.0013	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—liver cancer	0.000558	0.00129	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—liver cancer	0.000558	0.00129	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000553	0.00128	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—liver cancer	0.000548	0.00127	CcSEcCtD
Duloxetine—Haemoglobin—Epirubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—liver cancer	0.000542	0.00125	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—liver cancer	0.000542	0.00125	CcSEcCtD
Duloxetine—Haemorrhage—Epirubicin—liver cancer	0.000541	0.00125	CcSEcCtD
Duloxetine—Hepatitis—Epirubicin—liver cancer	0.000541	0.00125	CcSEcCtD
Duloxetine—Hypoaesthesia—Epirubicin—liver cancer	0.000538	0.00124	CcSEcCtD
Duloxetine—Pharyngitis—Epirubicin—liver cancer	0.000537	0.00124	CcSEcCtD
Duloxetine—Urinary tract disorder—Epirubicin—liver cancer	0.000534	0.00124	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—liver cancer	0.000533	0.00123	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—liver cancer	0.000532	0.00123	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—liver cancer	0.00053	0.00123	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—liver cancer	0.000527	0.00122	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—liver cancer	0.000526	0.00122	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—liver cancer	0.000521	0.00121	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—liver cancer	0.000512	0.00118	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—liver cancer	0.000506	0.00117	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—liver cancer	0.000504	0.00117	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—liver cancer	0.000503	0.00116	CcSEcCtD
Duloxetine—Flushing—Epirubicin—liver cancer	0.000502	0.00116	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—liver cancer	0.000502	0.00116	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—liver cancer	0.000501	0.00116	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—liver cancer	0.000501	0.00116	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—liver cancer	0.000498	0.00115	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—liver cancer	0.000497	0.00115	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—liver cancer	0.000494	0.00114	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—liver cancer	0.000493	0.00114	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—liver cancer	0.000492	0.00114	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—liver cancer	0.000491	0.00114	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—liver cancer	0.000491	0.00113	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—liver cancer	0.000489	0.00113	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—liver cancer	0.000488	0.00113	CcSEcCtD
Duloxetine—Chills—Epirubicin—liver cancer	0.000485	0.00112	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—liver cancer	0.000483	0.00112	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—liver cancer	0.000482	0.00112	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—liver cancer	0.000478	0.00111	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—liver cancer	0.000474	0.0011	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—liver cancer	0.000473	0.00109	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—liver cancer	0.000471	0.00109	CcSEcCtD
Duloxetine—Erythema—Epirubicin—liver cancer	0.000471	0.00109	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—liver cancer	0.000468	0.00108	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—liver cancer	0.000467	0.00108	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—liver cancer	0.000465	0.00107	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—liver cancer	0.000465	0.00107	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—liver cancer	0.000464	0.00107	CcSEcCtD
Duloxetine—Tension—Epirubicin—liver cancer	0.000462	0.00107	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—liver cancer	0.000461	0.00107	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—liver cancer	0.000457	0.00106	CcSEcCtD
Duloxetine—Back pain—Epirubicin—liver cancer	0.000456	0.00105	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—liver cancer	0.000454	0.00105	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—liver cancer	0.000453	0.00105	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—liver cancer	0.000452	0.00105	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—liver cancer	0.000451	0.00104	CcSEcCtD
Duloxetine—Chills—Doxorubicin—liver cancer	0.000449	0.00104	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—liver cancer	0.000447	0.00103	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—liver cancer	0.000444	0.00103	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—liver cancer	0.000442	0.00102	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—liver cancer	0.000439	0.00101	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—liver cancer	0.000437	0.00101	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—liver cancer	0.000436	0.00101	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—liver cancer	0.000436	0.00101	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—liver cancer	0.000435	0.00101	CcSEcCtD
Duloxetine—Agitation—Epirubicin—liver cancer	0.000433	0.001	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—liver cancer	0.000429	0.000993	CcSEcCtD
Duloxetine—Tension—Doxorubicin—liver cancer	0.000428	0.000989	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—liver cancer	0.000427	0.000987	CcSEcCtD
Duloxetine—Malaise—Epirubicin—liver cancer	0.000425	0.000982	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—liver cancer	0.000423	0.000979	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—liver cancer	0.000423	0.000978	CcSEcCtD
Duloxetine—Syncope—Epirubicin—liver cancer	0.000422	0.000977	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—liver cancer	0.000422	0.000975	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—liver cancer	0.000422	0.000975	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—liver cancer	0.000419	0.000969	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—liver cancer	0.000416	0.000962	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—liver cancer	0.000414	0.000957	CcSEcCtD
Duloxetine—Cough—Epirubicin—liver cancer	0.000411	0.00095	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—liver cancer	0.000411	0.00095	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—liver cancer	0.000408	0.000944	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—liver cancer	0.000407	0.00094	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—liver cancer	0.000404	0.000935	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—liver cancer	0.000403	0.000931	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—liver cancer	0.000401	0.000927	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—liver cancer	0.000401	0.000927	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—liver cancer	0.000401	0.000927	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—liver cancer	0.000401	0.000926	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—liver cancer	0.0004	0.000924	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000398	0.000921	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—liver cancer	0.000396	0.000916	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—liver cancer	0.000393	0.000909	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—liver cancer	0.000392	0.000907	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—liver cancer	0.000392	0.000905	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—liver cancer	0.000391	0.000904	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—liver cancer	0.00039	0.000902	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—liver cancer	0.000388	0.000896	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—liver cancer	0.000385	0.00089	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—liver cancer	0.000384	0.000889	CcSEcCtD
Duloxetine—Oedema—Epirubicin—liver cancer	0.000384	0.000889	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—liver cancer	0.000383	0.000886	CcSEcCtD
Duloxetine—Infection—Epirubicin—liver cancer	0.000382	0.000883	CcSEcCtD
Duloxetine—Cough—Doxorubicin—liver cancer	0.00038	0.000879	CcSEcCtD
Duloxetine—Shock—Epirubicin—liver cancer	0.000378	0.000874	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—liver cancer	0.000378	0.000873	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—liver cancer	0.000377	0.000872	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—liver cancer	0.000376	0.00087	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—liver cancer	0.000376	0.00087	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—liver cancer	0.000375	0.000867	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—liver cancer	0.000373	0.000863	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—liver cancer	0.000372	0.000859	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—liver cancer	0.000371	0.000858	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—liver cancer	0.000371	0.000858	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—liver cancer	0.000371	0.000858	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—liver cancer	0.00037	0.000855	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000368	0.000852	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—liver cancer	0.000367	0.000848	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—liver cancer	0.000366	0.000847	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—liver cancer	0.000363	0.000839	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—liver cancer	0.000359	0.000829	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—liver cancer	0.000356	0.000822	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—liver cancer	0.000356	0.000822	CcSEcCtD
Duloxetine—Infection—Doxorubicin—liver cancer	0.000353	0.000817	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00035	0.00081	CcSEcCtD
Duloxetine—Shock—Doxorubicin—liver cancer	0.00035	0.000809	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—liver cancer	0.000349	0.000806	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—liver cancer	0.000348	0.000805	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—liver cancer	0.000348	0.000804	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—liver cancer	0.000347	0.000803	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—liver cancer	0.000345	0.000799	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—liver cancer	0.000345	0.000798	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—liver cancer	0.000344	0.000795	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—liver cancer	0.000342	0.00079	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—liver cancer	0.000339	0.000784	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—liver cancer	0.000338	0.000782	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—liver cancer	0.000334	0.000773	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000332	0.000767	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—liver cancer	0.000331	0.000766	CcSEcCtD
Duloxetine—Pain—Epirubicin—liver cancer	0.000329	0.00076	CcSEcCtD
Duloxetine—Constipation—Epirubicin—liver cancer	0.000329	0.00076	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000324	0.000749	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—liver cancer	0.000322	0.000744	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—liver cancer	0.000319	0.000738	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—liver cancer	0.000317	0.000732	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—liver cancer	0.000316	0.000731	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—liver cancer	0.000314	0.000727	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—liver cancer	0.000313	0.000724	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—liver cancer	0.000309	0.000715	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000307	0.00071	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—liver cancer	0.000307	0.000709	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—liver cancer	0.000305	0.000706	CcSEcCtD
Duloxetine—Pain—Doxorubicin—liver cancer	0.000304	0.000703	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—liver cancer	0.000304	0.000703	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—liver cancer	0.000304	0.000703	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—liver cancer	0.000304	0.000703	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—liver cancer	0.000293	0.000678	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000291	0.000672	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—liver cancer	0.000283	0.000655	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—liver cancer	0.000283	0.000653	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—liver cancer	0.000281	0.00065	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—liver cancer	0.000281	0.00065	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—liver cancer	0.000276	0.000638	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—liver cancer	0.000272	0.000629	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—liver cancer	0.000263	0.000608	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—liver cancer	0.000262	0.000606	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—liver cancer	0.000255	0.00059	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—liver cancer	0.000254	0.000588	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—liver cancer	0.000252	0.000582	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—liver cancer	0.000244	0.000565	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—liver cancer	0.000243	0.000563	CcSEcCtD
Duloxetine—Rash—Epirubicin—liver cancer	0.000242	0.00056	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—liver cancer	0.000242	0.00056	CcSEcCtD
Duloxetine—Headache—Epirubicin—liver cancer	0.000241	0.000557	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—liver cancer	0.000235	0.000544	CcSEcCtD
Duloxetine—Nausea—Epirubicin—liver cancer	0.000228	0.000528	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—liver cancer	0.000226	0.000523	CcSEcCtD
Duloxetine—Rash—Doxorubicin—liver cancer	0.000224	0.000519	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—liver cancer	0.000224	0.000518	CcSEcCtD
Duloxetine—Headache—Doxorubicin—liver cancer	0.000223	0.000515	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—liver cancer	0.000211	0.000488	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—PRKCE—liver cancer	5.26e-05	0.000361	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—RAF1—liver cancer	5.23e-05	0.00036	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—liver cancer	5.23e-05	0.000359	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	5.22e-05	0.000358	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—liver cancer	5.18e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CSF2—liver cancer	5.12e-05	0.000352	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	4.99e-05	0.000343	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CPT1B—liver cancer	4.95e-05	0.00034	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLUL—liver cancer	4.95e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADAM17—liver cancer	4.91e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCE—liver cancer	4.86e-05	0.000334	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—liver cancer	4.81e-05	0.000331	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CD—liver cancer	4.8e-05	0.00033	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—liver cancer	4.8e-05	0.00033	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NR1H4—liver cancer	4.77e-05	0.000328	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTA3—liver cancer	4.69e-05	0.000322	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CSF2—liver cancer	4.65e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—F2—liver cancer	4.63e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSMA4—liver cancer	4.62e-05	0.000317	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSMD10—liver cancer	4.62e-05	0.000317	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CB—liver cancer	4.61e-05	0.000317	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—liver cancer	4.6e-05	0.000316	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.54e-05	0.000312	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—liver cancer	4.45e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CG—liver cancer	4.43e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CSF2—liver cancer	4.3e-05	0.000295	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTA4—liver cancer	4.29e-05	0.000295	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RAF1—liver cancer	4.29e-05	0.000295	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADAM17—liver cancer	4.27e-05	0.000293	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—H2AFX—liver cancer	4.24e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—liver cancer	4.23e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—F2—liver cancer	4.2e-05	0.000289	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CPT1B—liver cancer	4.19e-05	0.000288	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLUL—liver cancer	4.19e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CB—liver cancer	4.19e-05	0.000288	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTA2—liver cancer	4.18e-05	0.000287	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—liver cancer	4.09e-05	0.000281	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NR1H4—liver cancer	4.04e-05	0.000278	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTA1—liver cancer	4.04e-05	0.000277	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—liver cancer	4.02e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—F2—liver cancer	4.02e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSMD10—liver cancer	4.01e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSMA4—liver cancer	4.01e-05	0.000276	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAT2—liver cancer	3.99e-05	0.000274	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTA3—liver cancer	3.98e-05	0.000273	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—liver cancer	3.95e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CD—liver cancer	3.89e-05	0.000268	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—liver cancer	3.85e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—liver cancer	3.84e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—liver cancer	3.83e-05	0.000263	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDOB—liver cancer	3.83e-05	0.000263	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—liver cancer	3.78e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—F2—liver cancer	3.65e-05	0.000251	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CRABP1—liver cancer	3.65e-05	0.000251	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTA4—liver cancer	3.64e-05	0.00025	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—liver cancer	3.62e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCE—liver cancer	3.58e-05	0.000246	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.55e-05	0.000244	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTA2—liver cancer	3.54e-05	0.000243	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CD—liver cancer	3.54e-05	0.000243	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—liver cancer	3.5e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—liver cancer	3.49e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK14—liver cancer	3.48e-05	0.000239	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTA1—liver cancer	3.42e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—liver cancer	3.41e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CB—liver cancer	3.39e-05	0.000233	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—liver cancer	3.39e-05	0.000233	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CD—liver cancer	3.38e-05	0.000232	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAT2—liver cancer	3.38e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—F2—liver cancer	3.37e-05	0.000232	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—liver cancer	3.34e-05	0.000229	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.25e-05	0.000223	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOB—liver cancer	3.24e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—liver cancer	3.23e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—liver cancer	3.23e-05	0.000222	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HPGDS—liver cancer	3.19e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CSF2—liver cancer	3.17e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAF1—liver cancer	3.16e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—H2AFX—liver cancer	3.12e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—liver cancer	3.12e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCE—liver cancer	3.11e-05	0.000213	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CRABP1—liver cancer	3.09e-05	0.000212	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—liver cancer	3.08e-05	0.000212	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—liver cancer	3.07e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—liver cancer	3.03e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—liver cancer	2.95e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—liver cancer	2.94e-05	0.000202	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMD10—liver cancer	2.84e-05	0.000195	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMA4—liver cancer	2.84e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—liver cancer	2.84e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—liver cancer	2.83e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—liver cancer	2.82e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—liver cancer	2.81e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—liver cancer	2.81e-05	0.000193	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.78e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—liver cancer	2.78e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT2—liver cancer	2.77e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—liver cancer	2.75e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—liver cancer	2.74e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—H2AFX—liver cancer	2.71e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—liver cancer	2.71e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGDS—liver cancer	2.7e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.69e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—liver cancer	2.68e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2E1—liver cancer	2.6e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—liver cancer	2.58e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK14—liver cancer	2.56e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—liver cancer	2.55e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—liver cancer	2.53e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—liver cancer	2.51e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—liver cancer	2.48e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—liver cancer	2.47e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—liver cancer	2.47e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—liver cancer	2.46e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—liver cancer	2.45e-05	0.000168	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.45e-05	0.000168	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYCS—liver cancer	2.43e-05	0.000167	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.42e-05	0.000166	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMD10—liver cancer	2.41e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMA4—liver cancer	2.41e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT1—liver cancer	2.39e-05	0.000164	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—liver cancer	2.39e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—liver cancer	2.38e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—liver cancer	2.38e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—liver cancer	2.36e-05	0.000162	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT2—liver cancer	2.34e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—liver cancer	2.32e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—liver cancer	2.3e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—liver cancer	2.27e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—liver cancer	2.27e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—liver cancer	2.26e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—liver cancer	2.24e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—liver cancer	2.23e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK14—liver cancer	2.23e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—liver cancer	2.21e-05	0.000152	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—liver cancer	2.21e-05	0.000152	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2E1—liver cancer	2.2e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—liver cancer	2.19e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—liver cancer	2.18e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—liver cancer	2.16e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—liver cancer	2.15e-05	0.000148	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—liver cancer	2.14e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—liver cancer	2.14e-05	0.000147	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.13e-05	0.000147	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—liver cancer	2.11e-05	0.000145	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—liver cancer	2.09e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—liver cancer	2.09e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—liver cancer	2.08e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—liver cancer	2.07e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—liver cancer	2.07e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—liver cancer	2.06e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—liver cancer	2.06e-05	0.000142	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYCS—liver cancer	2.06e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—liver cancer	2.05e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—liver cancer	2.02e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT1—liver cancer	2.02e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—liver cancer	1.97e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—liver cancer	1.94e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—liver cancer	1.93e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—liver cancer	1.91e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	1.88e-05	0.000129	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—liver cancer	1.87e-05	0.000128	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—liver cancer	1.87e-05	0.000128	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—liver cancer	1.82e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—liver cancer	1.82e-05	0.000125	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—liver cancer	1.82e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—liver cancer	1.81e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	1.8e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—liver cancer	1.79e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—liver cancer	1.79e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—liver cancer	1.78e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—liver cancer	1.78e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—liver cancer	1.77e-05	0.000122	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—liver cancer	1.74e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—liver cancer	1.74e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—liver cancer	1.71e-05	0.000117	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—liver cancer	1.71e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—liver cancer	1.69e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—liver cancer	1.68e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—liver cancer	1.67e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—liver cancer	1.67e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—liver cancer	1.66e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—liver cancer	1.64e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.63e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—liver cancer	1.63e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—liver cancer	1.63e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—liver cancer	1.62e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—liver cancer	1.61e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—liver cancer	1.58e-05	0.000109	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—liver cancer	1.58e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—liver cancer	1.58e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.58e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.58e-05	0.000108	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.54e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.54e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.51e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—liver cancer	1.51e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.48e-05	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—liver cancer	1.48e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.47e-05	0.000101	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—liver cancer	1.46e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—liver cancer	1.46e-05	0.0001	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—liver cancer	1.45e-05	9.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—liver cancer	1.45e-05	9.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—liver cancer	1.45e-05	9.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—liver cancer	1.45e-05	9.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.42e-05	9.77e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—liver cancer	1.42e-05	9.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—liver cancer	1.41e-05	9.71e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—liver cancer	1.41e-05	9.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—liver cancer	1.41e-05	9.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.4e-05	9.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—liver cancer	1.39e-05	9.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—liver cancer	1.37e-05	9.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.37e-05	9.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.34e-05	9.18e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—liver cancer	1.33e-05	9.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.33e-05	9.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—liver cancer	1.31e-05	8.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.3e-05	8.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.3e-05	8.93e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—liver cancer	1.29e-05	8.84e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—liver cancer	1.27e-05	8.72e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—liver cancer	1.24e-05	8.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.23e-05	8.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—liver cancer	1.23e-05	8.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—liver cancer	1.22e-05	8.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—liver cancer	1.21e-05	8.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—liver cancer	1.2e-05	8.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—liver cancer	1.14e-05	7.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.13e-05	7.78e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—liver cancer	1.12e-05	7.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—liver cancer	1.11e-05	7.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—liver cancer	1.09e-05	7.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—liver cancer	1.08e-05	7.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—liver cancer	1.07e-05	7.38e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—liver cancer	1.05e-05	7.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—liver cancer	1.03e-05	7.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—liver cancer	9.83e-06	6.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—liver cancer	9.64e-06	6.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—liver cancer	9.5e-06	6.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—liver cancer	9.33e-06	6.41e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—liver cancer	9.07e-06	6.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—liver cancer	8.92e-06	6.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—liver cancer	8.54e-06	5.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—liver cancer	7.88e-06	5.41e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—liver cancer	6.84e-06	4.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—liver cancer	5.79e-06	3.98e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—liver cancer	5.58e-06	3.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—liver cancer	4.73e-06	3.25e-05	CbGpPWpGaD
